Skip to Content

Hikma Pharmaceuticals PLC - Stock Quote HKMPF

Rating as of

Morningstar's Hikma Pharmaceuticals PLC Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Hikma Pharmaceuticals PLC's Company Profile

Business Description

Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

1 New Burlington Place
London, W1S 2HR, United Kingdom
T +44 2073992760
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Fiscal Year End Dec 31, 2022
Stock Type
Employees 8,700